Monte Rosa Therapeutics reported interim Phase I results for MRT-8102 showing pronounced degradation of the NEK7 protein target and a sharp reduction in key inflammation biomarkers. These findings, presented at the Recent Advances in Immunology Conference, demonstrated up to 80% target engagement in healthy volunteers and a consistent decline of C-reactive protein levels by approximately 60% over a two-week dosing period. Investor response was swift, driving the stock up by 45% on heavy turnover, as market participants anticipated a fast-track regulatory pathway for this potential first-in-class inflammation therapy.

Jefferies raised its recommendation on GLUE shares to Buy, citing the strength of the MRT-8102 data and revising its 12-month price target upward by nine dollars. Shortly thereafter, Zacks Investment Research elevated the company to a Zacks Rank #1 (Strong Buy), highlighting an upward revision in consensus earnings estimates for the next two fiscal years. Both firms pointed to improved probability of late-stage trial success and attractive risk/reward given Monte Rosa’s robust cash runway and development pipeline expansion plans.

Following the data release and analyst upgrades, GLUE shares traded at volumes exceeding 22.7 million shares, well above the three-month daily average. The stock established a fresh one-year high during the session before settling back, underscoring elevated volatility. Short interest fell by 15% over the past month, while institutional holdings ticked higher, suggesting growing conviction among major funds. These metrics signal sustained market focus on Monte Rosa’s clinical milestones and potential partnership opportunities for its degrader platform.